**PURPOSE:** Arteriovenous malformation (AVM) is a locally destructive congenital vascular anomaly that enlarges over time. We previously reported that AVMs contain somatic mutations in the *MAP2K1* gene, and that the mutation is isolated to the endothelial cell (EC). The purpose of this study was to determine the effects of *MAP2K1* mutations in ECs on its signaling pathway.

**METHODS:** Human AVM-ECs were collected during a clinically-indicated procedure. *MAP2K1* mutations (K57N) were confirmed in the ECs using droplet digital PCR (ddPCR). We also engineered wild-type endothelial colony forming cells (ECFCs) with the *MAP2K1* (K57N) mutation. Patient-derived *MAP2K1*-AVM ECs and engineered *MAP2K1*-ECFCs were compared to control ECs: human white adipose (HWAT-ECs), ECFCs + empty vector, and ECFCs + wild-type *MAP2K1* vector. Western blot analysis was used to assess cell signaling along the RAS/MAPK pathway (e.g., baseline and phosphorylated *MEK1 and ERK1/2*). Densitometry quantification was performed with Image Studio™ Lite (Version 5.2).

**RESULTS:** Human *MAP2K1*-AVM ECs had consistent baseline *MEK1* and *ERK1/2* expression with controls; however, *MAP2K1*-AVM ECs produced 176% more active/phosphorylated *ERK1/2* than non-mutant ECs. Similarly, ECFCs engineered to overexpress mutant *MAP2K1* demonstrated 433% more phosphorylated *ERK1/2* expression than control ECFCs.

**CONCLUSIONS:** *MAP2K1* mutations in both human-derived AVM ECs as well as in engineered ECs activate the RAS/MAPK signaling pathway by increasing phosphorylation of ERK1/2, which is the downstream target of MAP2K1. Pharmacotherapy that inhibits the activating function of the mutation may inhibit the growth of AVMs.
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